Skip to main content

EBS

Stock

EBS

Stock
Health Care
Drug Manufacturers - Specialty & Generic

Performance overview

EBS Price
Price Chart

Forward-looking statistics

Beta
2.45
Risk
100.00%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Emergent BioSolutions Inc offers public health products to the government and healthcare providers. The company operates across three different segments, namely Commercial, Products, and Services. The key revenue is generated through the commercial segment which consists of NARCAN and other commercial products.

Company info

SectorHealth Care
IndustryDrug Manufacturers - Specialty & Generic
Employees2K
Market cap$324.4M

Fundamentals

Enterprise value$869.9M
Revenue$965.4M
Revenue per employee—
Profit margin-13.63%
Debt to equity121.71

Security info

ExchangeNyse American
Type of shareCommon Stock
Earnings per share (EPS)-$2.58
Dividend per share—
Revenue per share$18.03
Avg trading volume (30 day)$9M
Avg trading volume (10 day)$14M
Put-call ratio—

Macro factor sensitivity

Growth+4.7
Credit+6.1
Liquidity-4.4
Inflation+1.0
Commodities+1.8
Interest Rates-0.2

Valuation

Dividend yield0.00%
PEG Ratio2.34
Price to sales0.39
P/E Ratio2.34
Enterprise Value to Revenue0.90
Price to book0.69

Upcoming events

Next earnings dayMay 8, 2025
Next dividend day—
Ex. dividend dayAugust 1, 2016

News

5 Broker-Loved Stocks Amid EU Tariff Pause & Consumer Confidence Boost

Broker-favored picks like BYON, BTSG, ACDVF, EBS, and ADNT are worth monitoring amid EU tariff delay and rising consumer confidence.

Zacks Investment Research (May 29, 2025)
Mpox Vaccine Player Emergent BioSolutions Stock Jumps On Upbeat Annual Forecast, Expects Smaller Losses In 2024

On Thursday, Emergent BioSolutions Inc. EBS stock is trading higher on mixed third-quarter earnings and a new mpox trial in Africa.

Benzinga (November 7, 2024)
Upside for Emergent Bio if they can get Mpox vaccine rollout right, says Mizuho's Jared Holz

Jared Holz, Mizuho, joins 'Fast Money' to talk opportunities in pharma investing following approval of Emergent Bio's Mpox vaccine.

CNBC Television (August 30, 2024)
Health stocks jump as WHO declares mpox global health emergency

Shares of Danish vaccine maker Bavarian Nordic jumped as much as 17% Thursday amid a wider rally for associated healthcare stocks. It comes after the World Health Organization declared an escalating mpox outbreak in Africa as a public health emergency.

CNBC (August 15, 2024)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free